The life sciences sector encompasses pharmaceuticals, biotechnology, medical devices, diagnostics, and research tools. As of 2025, the largest players by pharmaceutical revenue are:
The global life science market size is calculated at US$ 88.2 billion in 2024, grew to US$ 98.63 billion in 2025, and is projected to reach around US$ 269.56 billion by 2034. The market is expanding at a CAGR of 11.82% between 2025 and 2034.
Role & Responsibility: Pfizer is a leading global biopharmaceutical company committed to discovering, developing, and manufacturing innovative medicines and vaccines.
Contribution: Pfizer has been instrumental in developing vaccines and treatments for various diseases, including the COVID-19 vaccine in collaboration with BioNTech.
Challenges: The company faces challenges such as patent expirations, pricing pressures, and the need to diversify its portfolio beyond COVID-19-related products.
Strategies: Pfizer focuses on expanding its oncology and immunology portfolios, investing in mRNA technology, and pursuing strategic acquisitions.
Recent Developments:
Q2 2025 Financials: Pfizer reported revenues of $14.65 billion, a 10% increase year-over-year. The company raised its full-year adjusted EPS guidance to a range of $2.90 to $3.10.
Acquisition of Metsera: Pfizer announced plans to acquire Metsera, a biotechnology firm focused on obesity treatment, for up to $7.3 billion. This move aims to strengthen Pfizer's position in the growing obesity treatment market.
Role & Responsibility: Johnson & Johnson is a diversified healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.
Contribution: The company has made significant contributions through its pharmaceuticals, medical devices, and consumer health products.
Challenges: J&J faces challenges related to litigation risks, regulatory scrutiny, and the need to innovate in a competitive healthcare landscape.
Strategies: The company focuses on advancing its pipeline in immunology and oncology, expanding its MedTech segment, and enhancing operational efficiencies.
Recent Developments:
Q2 2025 Financials: Johnson & Johnson reported Q2 2025 revenues of $23.7 billion, a 5.8% increase year-over-year. The company raised its full-year 2025 revenue outlook to $90.6 billion.
Recognition: J&J was named a 2025 Fortune World's Most Admired Company, reflecting its strong reputation in the healthcare industry.
Role & Responsibility: AbbVie is a global biopharmaceutical company that discovers, develops, and markets advanced therapies that address some of the world's most complex and serious diseases.
Contribution: AbbVie has made significant contributions through its immunology, oncology, and neuroscience portfolios, including the development of Humira, Rinvoq, and Venclexta.
Challenges: The company faces challenges related to the transition from Humira to newer therapies and the need to sustain growth in a competitive market.
Strategies: AbbVie focuses on expanding its immunology and neuroscience portfolios, investing in research and development, and pursuing strategic acquisitions.
Recent Developments:
Q2 2025 Financials: AbbVie reported Q2 2025 revenues of $15.42 billion, a 6.6% increase year-over-year. The company raised its full-year adjusted EPS guidance to a range of $11.00 to $11.20.
Portfolio Growth: AbbVie experienced significant growth in its immunology and neuroscience portfolios, with notable increases in sales of Rinvoq and Venclexta.
Role & Responsibility: Merck is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.
Contribution: Merck has made significant contributions through its oncology therapies, vaccines, and animal health products, including the development of Keytruda and Gardasil.
Challenges: The company faces challenges related to the upcoming loss of exclusivity for Keytruda, pricing pressures, and the need to diversify its portfolio.
Strategies: Merck focuses on expanding its oncology and vaccine portfolios, investing in research and development, and pursuing strategic partnerships.
Recent Developments:
Q2 2025 Financials: Merck reported Q2 2025 revenues of $15.8 billion, a 2% decrease year-over-year. The company anticipates full-year 2025 sales to be between $64.3 billion and $65.3 billion.
Challenges: Merck faced challenges with the halt in shipments of its Gardasil vaccine to China, impacting its sales forecasts.
Role & Responsibility: Roche is a global healthcare company that operates in the fields of pharmaceuticals and diagnostics, aiming to improve lives through innovative medicines and diagnostic tools.
Contribution: Roche has made significant contributions through its oncology therapies, diagnostics, and personalized healthcare solutions.
Challenges: The company faces challenges related to pricing pressures, market access issues, and the need to innovate in a competitive healthcare landscape.
Strategies: Roche focuses on expanding its oncology and diagnostics portfolios, investing in personalized healthcare, and enhancing operational efficiencies.
Recent Developments:
H1 2025 Financials: Roche reported first-half 2025 sales of CHF 30.9 billion, a 7% increase year-over-year. The company confirmed its full-year outlook based on strong results.
Clinical Trials: Roche initiated a Phase III trial for Actemra/RoActemra in July 2025, aiming to expand its portfolio in immunology.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
